Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
41 hedge funds and large institutions have $8.53M invested in Sio Gene Therapies Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 8 closing their positions.
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
30% less capital invested
Capital invested by funds: $12.1M → $8.53M (-$3.62M)
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.25M |
| 2 |
NM
Newtyn Management
New York
|
+$586K |
| 3 |
Jane Street
New York
|
+$38.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$23K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$449K |
| 2 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
-$211K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$86.1K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$70.3K |
| 5 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$60K |
SIOX Hedge Fund Activity: Q2 2022 in Review
41 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2022, worth a combined $8.53M — down 30% from $12.1M a quarter earlier.
Fund positioning in SIOX was balanced in Q2 2022: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 14 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $1.25M. The largest seller was Prosight Management, exiting entirely with an estimated $449K sold.
- 41 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $8.53M of Sio Gene Therapies Inc. Common Stock stock for Q2 2022, down 30% quarter-over-quarter.
- 8 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2022 and 8 closed out, a net change of 0 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $1.25M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2022 was Prosight Management, an estimated $449K sold.
Based on aggregated 13F filings for Q2 2022.